SEC Form 424B3 filed by Fortress Biotech Inc.

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-279516

AMENDMENT NO. 1 dated October 25, 2024

to PROSPECTUS SUPPLEMENT dated August 2, 2024

(to Prospectus dated May 30, 2024)    

Up to $6,500,000

of Common Stock

This prospectus supplement (“Prospectus Supplement”) amends and supplements the information in our prospectus dated May 30, 2024 (the “Base Prospectus”), as supplemented by our prospectus supplement dated August 2, 2024 (the “Initial Prospectus Supplement” and together with the Base Prospectus, the “Prospectus”), filed pursuant to our registration statement on Form S-3 (File No. 333-279516) (the “Registration Statement”), covering the offering, issuance and sale by us of our common stock that may be issued and sold under the At Market Issuance Sales Agreement entered into with H.C. Wainwright & Co., LLC and Dawson James Securities, Inc. (each, an “Agent” and together, the “Agents”), dated May 29, 2020 (the “Sales Agreement”). This Prospectus Supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus, and any future amendments or supplements thereto.

In accordance with the terms of the Sales Agreement, under this Prospectus Supplement and accompanying Prospectus we may offer and sell shares of our common stock, $0.001 par value per share, from time to time through the Agents, acting as agent.

We are filing this Prospectus Supplement to amend the Prospectus to update the amount of common stock we are eligible to sell under our Registration Statement pursuant to General Instruction I.B.6 of Form S-3. On March 28, 2024, the date we filed our Annual Report on Form 10-K for the year ended December 31, 2023, our Registration Statement became subject to the offering limits set forth in General Instruction I.B.6 of Form S-3. Pursuant to General Instruction I.B.6, and in accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $6,500,000 from time to time through or to the Agents. In the event that we become eligible to sell additional amounts under the Sales Agreement in accordance with General Instruction I.B.6 or otherwise, we will file another prospectus supplement prior to making such additional sales. 

Our common stock is listed on the Nasdaq Capital Market under the symbol “FBIO”. As of October 25, 2024, the aggregate market value of our common stock held by non-affiliates, or the public float, pursuant to General Instruction I.B.6 of Form S-3 was $47,303,566, which was calculated based on 22,001,659 shares of our common stock outstanding held by non-affiliates as of October 16, 2024 at a price of $2.15 per share, the last reported sale price for our common stock on August 26, 2024. Pursuant to General Instruction I.B.6 of Form S-3, in no event may we offer securities pursuant to this Prospectus Supplement with an aggregate offering price of more than one-third of our public float or approximately $6,500,000, in any 12-calendar month period for as long as our public float is less than $75,000,000. As of the date hereof, we have offered and sold $9,088,671 of securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-calendar month period that ends on and includes the date hereof (but excludes this offering).

Investing in our common stock involves risks. See “Risk Factors” beginning on page S-3 of the Initial Prospectus Supplement and the risks and uncertainties described in the documents we file with the Securities and Exchange Commission that are incorporated in this Prospectus Supplement and the Prospectus by reference for certain risks and uncertainties relating to an investment in our common stock. 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Prospectus Supplement and the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this Prospectus Supplement is October 25, 2024.